VESPER
Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer
- NCT01812369 ↗
- Completed
- University Hospital, Rouen
- Deep
We haven't built an HCP commentary report on VESPER (GC in locally advanced bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 40 newest of 67 indexed sources (Jun 2023 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether ddMVAC is the preferred neoadjuvant regimen
- How treatment duration should be chosen
- How ddMVAC tolerability and patient suitability should shape regimen choice
- Whether the neoadjuvant survival signal is sufficient to guide treatment
Also discussed: molecular subtyping.
Indexed commentary on VESPER so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 59 | |
| YouTube | 4 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Study of Gemcitabine/Cisplatine (GC) Versus High-dose Intensity Methotrexate, Vinblastine, Doxorubicine and Cisplatin (HD-MVAC) in the Perioperative Setting for Patients With Locally Advanced Transitional Cell Cancer of the Bladder
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Bladder Cancer
- Interventions
- GEMCITABINE CISPLATINE; METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
- Arms
- GC · Experimental
- MVAC-HD · Active comparator
- Enrollment
- 500
- Primary outcomes
- Progression-free survival (PFS) at 3 years
- Sponsor
- University Hospital, Rouen
- Start
- Feb 2013
- Primary completion
- Sep 25, 2023
- Results posted
- No
- Registry record
- NCT01812369 · updated Oct 6, 2025
Publications
linked from the registry- Pfister C, Harter V, Fontugne J, Allory Y, Culine S; VESPER Trial Investigators. Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. Eur Urol Oncol. 2026 Jan 22:S2588-9311(26)00004-0. doi: 10.1016/j.euo.2026.01.003. Online ahead of print. PubMed 41577609
- Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. PubMed 38142702
- Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7. PubMed 35254888